<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144975</url>
  </required_header>
  <id_info>
    <org_study_id>X052118</org_study_id>
    <nct_id>NCT01144975</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XOMA (US) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XOMA (US) LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that XOMA 052 is likely to improve glycemic control in subjects with&#xD;
      Type 2 Diabetes Mellitus.&#xD;
&#xD;
      The purpose of this study is to determine whether XOMA 052 improves glycemic control in&#xD;
      subjects on Metformin monotherapy whose diabetes is still not adequately controlled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, daily fasting blood glucose measured by the subject using a glucose monitor, and treatment-emergent adverse events.</measure>
    <time_frame>Day 0 pre-dose through Day 420</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of XOMA 052 from serum samples collected at time points specified in the protocol.</measure>
    <time_frame>Day 0 pre-dose through Day 420</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-inflammatory activity measured by hs-CRP and cytokines collected at time points specified in the protocol.</measure>
    <time_frame>Day 0 pre-dose through Day 420</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-diabetic activity measured by HbA1c, FPG, OGTT, C-peptide, and insulin collected at time points specified in the protocol.</measure>
    <time_frame>Day 0 pre-dose through Day 420</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>XOMA 052</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XOMA 052</intervention_name>
    <description>Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)</description>
    <arm_group_label>XOMA 052</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with T2D (disease duration &gt;= 6 months)&#xD;
&#xD;
          -  HbA1c measurements &gt;= 7.0% and &lt;= 10.0%&#xD;
&#xD;
          -  On a stable regimen of metformin monotherapy&#xD;
&#xD;
          -  Age &gt;= 18 and &lt;= 75&#xD;
&#xD;
          -  Stable diet and exercise regimen&#xD;
&#xD;
          -  BMI &lt;= 40 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant signs and symptoms of uncontrolled hyperglycemia (i.e., polyuria,&#xD;
             polydipsia, or polyphagia)&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt; 170 mmHg and/or diastolic &gt; 110 mmHg)&#xD;
&#xD;
          -  Known to be positive for Hep B surface antigen (HBsAg), Hep C virus (HCV), or HIV&#xD;
&#xD;
          -  History of allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies&#xD;
&#xD;
          -  Advanced stage heart failure (New York Heart Association [NYHA] class 3 or 4)&#xD;
&#xD;
          -  Pulmonary disease requiring medication other than inhaled corticosteroid s&#xD;
&#xD;
          -  History of tuberculosis or positive PPD test.&#xD;
&#xD;
          -  Active leg, foot, or decubitus ulcer&#xD;
&#xD;
          -  Any significant inflammatory, rheumatologic, or systemic autoimmune disease&#xD;
&#xD;
          -  History or any symptoms of a demyelinating disease&#xD;
&#xD;
          -  History of severe non-proliferative or proliferative retinopathy&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Type 2</keyword>
  <keyword>Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

